3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
2
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
9
Prostatic Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Recurrence
2
Mesothelioma, Malignant
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Interventions
Temozolomide
69
Bevacizumab
40
Radiotherapy
22
Magnetic Resonance Spectroscopy
20
Irinotecan
17
Specimen Handling
10
Carboplatin
10
Carmustine
9
X-Rays
7
Radiation
7
olaparib
6
Surgical Procedures, Operative
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Nivolumab
6
Everolimus
6
Cyclophosphamide
6
Biopsy
6
trametinib
5
Thalidomide
5
Cisplatin
5
pembrolizumab
4
palbociclib
4
fluorodopa F 18
4
erdafitinib
4
dabrafenib
4
Lomustine
4
Etoposide
4
Drug Therapy
4
Doxorubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Glioma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts